Development of Two Novel One-Step and Green Microwell Spectrophotometric Methods for High-Throughput Determination of Ceritinib, a Potent Drug for Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Background and Objectives: Ceritinib (CER) is a potent drug of the third-generation tyrosine kinase inhibitor class. CER has been approved for the treatment of patients with non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase (ALK) mutation gene. In the literature, there is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuhejail, Reem M., Alzoman, Nourah Z., Darwish, Ibrahim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608039/
https://www.ncbi.nlm.nih.gov/pubmed/37893531
http://dx.doi.org/10.3390/medicina59101813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608039/
https://www.ncbi.nlm.nih.gov/pubmed/37893531
http://dx.doi.org/10.3390/medicina59101813

Ejemplares similares